Evangeline Pierce

884 total citations · 1 hit paper
69 papers, 447 citations indexed

About

Evangeline Pierce is a scholar working on Dermatology, Immunology and Allergy and Physiology. According to data from OpenAlex, Evangeline Pierce has authored 69 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Dermatology, 43 papers in Immunology and Allergy and 21 papers in Physiology. Recurrent topics in Evangeline Pierce's work include Dermatology and Skin Diseases (65 papers), Allergic Rhinitis and Sensitization (32 papers) and Food Allergy and Anaphylaxis Research (26 papers). Evangeline Pierce is often cited by papers focused on Dermatology and Skin Diseases (65 papers), Allergic Rhinitis and Sensitization (32 papers) and Food Allergy and Anaphylaxis Research (26 papers). Evangeline Pierce collaborates with scholars based in United States, Spain and Germany. Evangeline Pierce's co-authors include Jonathan I. Silverberg, Jacob P. Thyssen, Hany Elmaraghy, María José Rueda, David Rosmarin, E. Serra‐Baldrich, Peter Lio, Amy M. DeLozier, Chitra R Natalie and Eric L. Simpson and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Allergy and Clinical Immunology and Journal of Investigative Dermatology.

In The Last Decade

Evangeline Pierce

53 papers receiving 437 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials

2023 72 citations Andrew Blauvelt, Jacob P. Thyssen et al. British Journal of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Evangeline Pierce United States	12	374	258	96	83	48	69	447
Jeremy Udkoff United States	10	324 0.9×	244 0.9×	89 0.9×	60 0.7×	34 0.7×	27	420
Paola Facheris Italy	14	367 1.0×	190 0.7×	89 0.9×	79 1.0×	151 3.1×	36	489
Anna Ascott United Kingdom	7	253 0.7×	173 0.7×	103 1.1×	42 0.5×	49 1.0×	14	312
Daniela Mikhaylov United States	10	201 0.5×	94 0.4×	49 0.5×	35 0.4×	64 1.3×	14	305
Girish C. Mohan United States	10	219 0.6×	104 0.4×	64 0.7×	37 0.4×	64 1.3×	13	346
Simon J Meggitt United Kingdom	3	385 1.0×	322 1.2×	103 1.1×	72 0.9×	57 1.2×	4	516
Zakiya P. Rice United States	8	154 0.4×	88 0.3×	61 0.6×	53 0.6×	26 0.5×	15	273
Sahil Sekhon United States	12	383 1.0×	166 0.6×	141 1.5×	74 0.9×	199 4.1×	24	546
William Romero United States	9	321 0.9×	201 0.8×	94 1.0×	79 1.0×	62 1.3×	24	378
Usman Chaudhry United States	5	429 1.1×	307 1.2×	200 2.1×	90 1.1×	118 2.5×	7	504

Countries citing papers authored by Evangeline Pierce

Since Specialization

Citations

This map shows the geographic impact of Evangeline Pierce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evangeline Pierce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evangeline Pierce more than expected).

Fields of papers citing papers by Evangeline Pierce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evangeline Pierce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evangeline Pierce. The network helps show where Evangeline Pierce may publish in the future.

Co-authorship network of co-authors of Evangeline Pierce

This figure shows the co-authorship network connecting the top 25 collaborators of Evangeline Pierce. A scholar is included among the top collaborators of Evangeline Pierce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evangeline Pierce. Evangeline Pierce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stein‐Gold, Linda, Peter Lio, Raj Chovatiya, et al.. (2025). Key Treatment Attributes and Preferences of Allergists and Dermatologists for Moderate-To-Severe Atopic Dermatitis: Results from a US-Based Real-World, Cross-Sectional Study. Journal of Allergy and Clinical Immunology. 155(2). AB209–AB209. 1 indexed citations

Alexis, Andrew, Jill Waibel, Paul F. Wallace, et al.. (2025). Lebrikizumab Improves Atopic Dermatitis in Adult and Adolescent Patients With Skin of Color: 16-Week Results From the ADmirable Study. SKIN The Journal of Cutaneous Medicine. 9(1). s515–s515.

Blauvelt, Andrew, Leon Kircik, Evangeline Pierce, et al.. (2025). Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis. Journal of Dermatological Treatment. 36(1). 2442720–2442720. 2 indexed citations

Alexis, Andrew, Jill Waibel, Paul F. Wallace, et al.. (2025). Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable Study. American Journal of Clinical Dermatology. 26(5). 803–817. 1 indexed citations

Guttman‐Yassky, Emma, Alan D. Irvine, Eric L. Simpson, et al.. (2025). Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe Atopic Dermatitis: Results Up to 3 Years From ADjoin. SKIN The Journal of Cutaneous Medicine. 9(1). s510–s510.

Chovatiya, Raj, Eric L. Simpson, Tilo Biedermann, et al.. (2025). Achieving Depth of Response in Skin Clearance and Itch Relief With Lebrikizumab is Associated With Minimal Impact of Atopic Dermatitis on Quality of Life. SKIN The Journal of Cutaneous Medicine. 9(1). s516–s516.

Mesinkovska, Natasha Atanaskova, Brett King, Sergio Vañó‐Galván, et al.. (2024). Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial. SHILAP Revista de lepidopterología. 3(2). 528–535. 3 indexed citations

Simpson, Eric L., Pablo Fernández‐Peñas, Marjolein de Bruin‐Weller, et al.. (2024). Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2). Advances in Therapy. 42(1). 132–143. 3 indexed citations

Silverberg, Jonathan I., Andreas Wollenberg, Linda Stein Gold, et al.. (2024). Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment. Dermatology and Therapy. 14(8). 2249–2260. 4 indexed citations

10.

Delbecque, Laure, et al.. (2024). Sleep-loss related to itch in atopic dermatitis: assessing content validity and psychometric properties of a patient-reported sleep-loss rating scale. Journal of Patient-Reported Outcomes. 8(1). 77–77. 1 indexed citations

11.

Yosipovitch, Gil, Peter Lio, David Rosmarin, et al.. (2024). 497 - Lebrikizumab in combination with topical corticosteroids maintains improvements in itch and sleep at 68 weeks in patients with moderate-to-severe atopic dermatitis. British Journal of Dermatology. 190(Supplement_2). ii6–ii7. 1 indexed citations

12.

Pierce, Evangeline, et al.. (2023). Impact Of Day-to-Day Sleep Disruption on The Burden of Disease In Moderate-severe Adult Atopic Dermatitis Patients. SKIN The Journal of Cutaneous Medicine. 7(2). s148–s148.

13.

Blauvelt, Andrew, Jacob P. Thyssen, Emma Guttman‐Yassky, et al.. (2023). Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. British Journal of Dermatology. 188(6). 740–748. 72 indexed citations breakdown →

14.

Craiglow, Brittany G., Yang Won Lee, Sergio Vañó‐Galván, et al.. (2023). 41915 Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials. Journal of the American Academy of Dermatology. 89(3). AB55–AB55. 1 indexed citations

15.

Silverberg, Jonathan I., Evangeline Pierce, Amber Reck Atwater, et al.. (2023). Disease burden among patients with atopic dermatitis treated with systemic therapy for 4–12 months: results from the CorEvitas Atopic Dermatitis Registry. Journal of Dermatological Treatment. 34(1). 2246601–2246601.

16.

Yosipovitch, Gil, Marjolein de Bruin‐Weller, Marni Wiseman, et al.. (2023). 41679 Lebrikizumab monotherapy improves quality of life through improvement in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis. Journal of the American Academy of Dermatology. 89(3). AB61–AB61. 1 indexed citations

17.

Piraccini, Bianca Maria, Manabu Ohyama, Brittany G. Craiglow, et al.. (2023). Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials. SKIN The Journal of Cutaneous Medicine. 7(2). s186–s186. 3 indexed citations

18.

Guttman‐Yassky, Emma, Stephan Weidinger, Jonathan I. Silverberg, et al.. (2023). 94 Maintenance of efficacy and safety with lebrikizumab up to one year of treatment in patients with moderate-to-severe atopic dermatitis with or without topical corticosteroids. Journal of Investigative Dermatology. 143(11). S348–S348. 2 indexed citations

19.

Silverberg, Jonathan I., Vivian Y. Shi, Andrew Alexis, et al.. (2023). Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry. Dermatology and Therapy. 13(9). 2045–2061. 4 indexed citations

20.

Egeberg, Alexander, Jacob P. Thyssen, Jashin J. Wu, Evangeline Pierce, & Jorge Alfonso Ross Terres. (2021). Treatment Patterns in Danish Patients with Atopic Dermatitis Before and After Hospital Referral. Dermatology and Therapy. 11(2). 499–512. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact